Get the Stockscreener App
18.91
5.70%
1.02
Dyne Therapeutics Inc stock is traded at $18.91, with a volume of 902.65K.
It is up +5.70% in the last 24 hours and up +2.22% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$17.89
Open:
$17.56
24h Volume:
902.65K
Relative Volume:
0.34
Market Cap:
$3.11B
Revenue:
-
Net Income/Loss:
$-412.89M
P/E Ratio:
-4.899
EPS:
-3.86
Net Cash Flow:
$-361.93M
1W Performance:
+5.06%
1M Performance:
+2.22%
6M Performance:
+88.16%
1Y Performance:
+32.98%
1-Day Range:
$17.45
$19.02
1-Week Range:
$17.11
$19.02
52-Week Range:
$6.36
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.91 | 2.95B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.65 | 119.22B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.05 | 77.93B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
844.02 | 52.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.34 | 44.66B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.68 | 37.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
(DYN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Pullback Watch: Can Dyne Therapeutics Inc scale operations efficientlyPortfolio Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-01-28 16:56:14 - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling a 117% Potential Upside in Biotechnology - DirectorsTalk Interviews
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? - The Globe and Mail
Dyne Therapeutics: 2026 Catalysts Point To Further Upside (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (DYN) Is Up 7.8% After Japan Grants Orphan Status To DM1 Drug Candidate - Sahm
FY2025 Earnings Forecast for DYN Issued By Lifesci Capital - MarketBeat
How Does Japan’s Orphan Nod Shape Dyne Therapeutics’ (DYN) Global Rare-Disease Strategy? - Yahoo Finance
(DYN) Risk Channels and Responsive Allocation - Stock Traders Daily
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - 富途资讯
CEO Change: What is Dyne Therapeutics Incs 5 year growth outlookQuarterly Portfolio Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Biotech Powerhouse with 134% Upside Potential - DirectorsTalk Interviews
JPMorgan Chase & Co. Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $16.00 - MarketBeat
JP Morgan Updates Dyne Therapeutics (DYN) with a Neutral Rating - GuruFocus
Dyne Therapeutics (DYN) Gains Orphan Drug Status in Japan for DM - GuruFocus
Dyne Therapeutics Receives Orphan Drug Designation in Japan - GlobeNewswire
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - Sahm
Campbell & CO Investment Adviser LLC Purchases Shares of 64,517 Dyne Therapeutics, Inc. $DYN - MarketBeat
Can Dyne Therapeutics Inc. scale operations efficientlyMarket Rally & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Why Dyne Therapeutics Stock Was Crushing it This Week - AOL.com
Jobs Data: Is Dyne Therapeutics Inc a turnaround storyWeekly Profit Report & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.9%Here's What Happened - MarketBeat
Is Dyne Therapeutics' (DYN) Late-Stage DMD Progress Redefining Its Rare Disease Investment Story? - simplywall.st
Analysts project 120% upside to Dyne Therapeutics, Inc. (DYN) - MSN
Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) - Insider Monkey
DYN: Transformative clinical data and commercial launches planned for 2026–2027 in DMD and DM1 - TradingView
DYN: Transformative DMD and DM1 therapies advance toward 2027 launches, backed by validated platform - TradingView
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Why Dyne Therapeutics Inc stock appeals to analystsEarnings Risk Report & Risk Managed Investment Signals - Bộ Nội Vụ
Fed Meeting: Why Dyne Therapeutics Inc stock attracts high net worth investorsLong Setup & Long-Term Safe Investment Plans - Bộ Nội Vụ
Aug Gainers: Why Dyne Therapeutics Inc stock is trending among retail tradersTrade Ideas & Real-Time Sentiment Analysis - moha.gov.vn
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - Investing News Network
Downgrade Watch: Can Dyne Therapeutics Inc weather a recessionTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors - Investing News Network
Day Trade: What is Dyne Therapeutics Incs 5 year growth outlookMarket Trend Report & Weekly Chart Analysis and Guides - baoquankhu1.vn
(DYN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How risky is Dyne Therapeutics Inc. stock now2025 Sector Review & Momentum Based Trading Signals - ulpravda.ru
Why hedge funds are buying Dyne Therapeutics Inc. stockJuly 2025 Market Mood & Detailed Earnings Play Strategies - ulpravda.ru
$350 million fundraise shows potential of novel DMD therapy - The Pharma Letter
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6%Here's What Happened - MarketBeat
Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus - TechStock²
Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus - ts2.tech
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.7%What's Next? - MarketBeat
Liquidity Mapping Around (DYN) Price Events - Stock Traders Daily
Dyne Therapeutics (DYN) climbs 9.5% on stellar results for DMD therapy candidate - MSN
Dyne Therapeutics Earnings Notes - Trefis
Free cash flow per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):